mTOR inhibitor; inhibits tumor growth in breast cancer cell lines (IC50 values are 1.6 and 4.3 nM for SKBr3 and BT474, respectively). Inhibits HIF-1α-mediated VEGF production in breast cancer cell lines (BT474 and MDA-MB-231). Directly inhibits serum and VEGF mediated endothelial cell proliferation and morphogenesis in vitro and vessel formation in vivo. Causes G1/S cell cycle arrest in multiple cancer cell lines. Antiangiogenic. Activates autophagy.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 1030.29. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||0.97 mL||4.85 mL||9.71 mL|
|5 mM||0.19 mL||0.97 mL||1.94 mL|
|10 mM||0.1 mL||0.49 mL||0.97 mL|
|50 mM||0.02 mL||0.1 mL||0.19 mL|
References are publications that support the biological activity of the product.
Wang et al (2012) Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus). DNA Cell Biol. 31 1095 PMID: 22320865
Del Bufalo et al (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66 5549 PMID: 16740688
Wu L et al (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65 2825 PMID: 15805283
Li et al (2013) The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 13 PMID: 23537100
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
If you know of a relevant reference for Temsirolimus, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Temsirolimus, Temsirolimus supplier, Breast, cancer, mTOR, inhibitors, inhibits, rapamycin, kinases, suppresses, cell, tumour, tumor, growth, VEGF, Vascular, endothelial, factor, CCI-779, Cell, Cycle, Inhibitors, Autophagy, 5264, Tocris Bioscience
Citations for Temsirolimus
Citations are publications that use Tocris products.
Currently there are no citations for Temsirolimus. Do you know of a great paper that uses Temsirolimus from Tocris? Please let us know.
Reviews for Temsirolimus
There are currently no reviews for this product. Be the first to review Temsirolimus and earn rewards!
Have you used Temsirolimus?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.